Skip to content

Study · Case report or series · n = 1 · 2026

1 result

Acute pancreatitis following semaglutide therapy: a case report.

Alduraibi RK, Fattouta NA, Altowayan YF

Annals of medicine and surgery (2012)4 Aug 2026

PMID42725314 (opens in a new tab)PMCIDPMC13561303 (opens in a new tab)DOI10.1097/ms9.0000000000005389 (opens in a new tab)PepBankPUB-42725314
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

BackgroundAcute pancreatitis (AP) is a potentially life-threatening condition that can result from various aetiologies. While gallstones and alcohol consumption are the most common causes, medications can also induce AP. In the absence of a clear cause, drug-induced acute pancreatitis (DIAP) may pose challenges for clinicians. This is especially true when addressing unusual and rare causes such as glucagon-like peptide-1 receptor agonists.Case presentationA 41-year-old Saudi man was admitted to the hospital with epigastric pain after receiving subcutaneous semaglutide for weight loss. Laboratory test results revealed AP.ConclusionsIn conclusion, semaglutide-induced acute pancreatitis is a rare but serious adverse effect. Clinicians should be aware of this potential adverse effect, particularly in patients without a history of diabetes mellitus who are using the drug for weight loss. Early recognition and discontinuation of the drug are crucial for the management of this condition.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    A 41-year-old man was admitted with epigastric pain after subcutaneous semaglutide for weight loss, and laboratory tests revealed acute pancreatitis.

    In plain wordsOne man developed acute pancreatitis after receiving semaglutide for weight loss.

    Peptide
    Semaglutide
    Outcome
    Not applicableAcute pancreatitis after semaglutide
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    A 41-year-old Saudi man was admitted to the hospital with epigastric pain after receiving subcutaneous semaglutide for weight loss.
    1 context sentence
    Summary · context
    Laboratory test results revealed AP.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.